Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

BRCA+ Patients May Have Higher Risk of Serous Uterine Cancers After RRSO

October 15th 2015

Dr. Noah Kauff discusses how hysterectomy, in addition to standard risk-reducing salpingo-oophorectomy (RRSO) measures, should be considered in BRCA+women to reduce the risk of serous uterine cancers.

TILs Emerge as Robust Biomarker, Shed Light on Immunotherapy Potential in TNBC

October 14th 2015

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

Dr. Kapoor on Multigene Panel Testing for Patients at Risk for Breast Cancer

September 26th 2015

Nimmi S. Kapoor, MD, surgical oncologist, Breastlink Laguna Hills and Breastlink Orange, discusses the benefits and safety of multigene panel testing in patients who are at risk for hereditary breast cancer.

Dr. Sherwell-Cabello on Prognostic Impact of TILs and SILs in TNBC

September 26th 2015

Santiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes and stromal-infiltrating lymphocytes in patients with triple-negative breast cancer (TNBC).

Most Brain Metastases Have Actionable Mutations Not Found in Primary Tumor

September 26th 2015

More than half of brain metastases harbored clinically actionable genetic alterations that were distinct from those associated with the primary tumor.

Deep Sequencing Reveals Possible Primary Resistance Mechanism in EGFR-Mutant NSCLC

September 9th 2015

Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.

Precision Medicine Modeling Helps Advance Colorectal Cancer Care

August 30th 2015

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

Cancer Immunotherapy Meets Precision Medicine in Biomarker Study

August 29th 2015

Mismatch repair deficiency may serve as an immuno-oncology biomarker and may illustrate the clinical utility of analyzing the number of mutations per tumor.

Dr. Gitlitz on EGFR Exon 20 Insertion Mutations in Lung Cancer

August 28th 2015

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

Rapidly Evolving Lung Cancer Treatment Landscape

August 27th 2015

Checkpoint Inhibitors for Malignant Pleural Mesothelioma

August 27th 2015

Immunotherapy AEs and Treatment Duration in NSCLC

August 27th 2015

Checkpoint Inhibitors in Small-Cell Lung Cancer

August 27th 2015

Frontline Immunotherapy Combinations for NSCLC

August 27th 2015

Checkpoint Inhibitor Biomarkers for Lung Cancer

August 27th 2015

Emerging Landscape of Immunotherapy in NSCLC

August 27th 2015

Bevacizumab in EGFR-Mutant NSCLC

August 27th 2015

Bevacizumab in Nonsquamous NSCLC

August 27th 2015

Bevacizumab in Malignant Pleural Mesothelioma

August 27th 2015

New Therapies for Squamous NSCLC

August 27th 2015

NEXT PAGE
PREVIOUS PAGE